Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
February 12, 2025 1:46 PM ESTStifel analyst Rick Wise reiterated a Buy rating and $90.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "Edwards' 4Q24 performance checked all the critical boxes, including: (1) mid-single-digit TAVR growth (5.3%), despite a 12.1% 4Q23 comp and selling day headwind, suggests that TAVR growth... More
Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance
February 11, 2025 4:17 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.59, $0.04 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.39 billion versus the consensus estimate of $1.36 billion.
GUIDANCE:
Edwards Lifesciences sees Q1 2025 EPS of $0.58-$0.64, versus the consensus of $0.59.... More
